Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CVR Medical Corp V.CVM.H

Alternate Symbol(s):  CRRVF

Healthcare Medical Devices
CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool, which complements other stroke screening technology such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA) and computed tomography angiography (CTA). The CSS is non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers.


TSXV:CVM.H - Post by User

CVR Medical Corp
Bullboard Posts
User Avatar Image
(2)
•••
Comment by Nastroon Aug 31, 2018 4:43pm
82 Views
Post# 28551186

RE:RE:RE:RE:RE:RE:RE:RE:Who started this rumor?

RE:RE:RE:RE:RE:RE:RE:RE:Who started this rumor?It wasn't their decision to delay the FDA submission.  At their meeting in March the FDA classified the CSS as 'moderate' rather than 'low' risk.  There is a significant difference between the 2.  The moderate classification has meant a very onerous validation of the software is required, running to something like 38,000 different lines of code.  Hence they had had to contract this out to a third party company to help them complete it and thus the time delay.  Hopefully submission will still be at the end of next month, at worst it should be by mid October.

The proposed restructure may relate to plans to delist in Toronto and go to one listing on the Nasdaq.  Whilst dilution is usually not great, in this instance it could be a real positive.  The Nasdaq is clearly where this should reside rather than the TSX which is dominated by natural resource companies.  The stock currently also suffers from a lack of liquidity which doesn't help either.

If you'd rather 'invest' in cannabis stocks then good luck with that.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities